Abstract:Abstract Dendritic cells (DCs) are professional antigen-presenting cells that are integral to the induction of primary, antigen-specific T cell responses. In the cancer setting, DCs mediate cross-priming of tumor-reactive T cells by presenting tumor antigens acquired from viable or dead cancer cells. Due to their unique functional properties, DCs have been utilized as both vectors and targets for immunological intervention in numerous diseases and are optimal candidates for vaccination protocols in cancer. In addition to their antigen presentation function(s), recent evidence suggests that DCs may also perform an innate immune effector function, with human DCs reported to mediate direct tumoricidal activity in vitro. However, the mechanism(s) by which DCs directly kill tumor cells remain unclear. The goal of this study is to further characterize the mechanism(s) associated with murine DC tumoricidal function and to determine whether and how this function may be enhanced to promote anti-tumor immune responses that translate into therapeutic effectiveness. One way we sought to enhance this DC effector function was through the genetic engineering of DCs themselves. After transduction with mIL-12 and/or mIL-18 cDNA using recombinant adenoviral vectors, DCs exhibited significantly elevated tumor killing activity. This was mediated, at least in part, by TNF ligand-receptor complexes, as demonstrated by antibody blocking assays. When injected in situ, these engineered DCs exhibited prolonged survival, in association with enhanced levels of tumor apoptosis proximal to imaged DCs and our capacity to image DC that had engulfed tumor apoptotic bodies. We also observed notable therapeutic benefits upon intratumoral delivery of these DCs in concert with an expanded in vivo repertoire of anti-tumor CD8+ T cells. In addition to DC modification, we also evaluated treatments applied to tumor cells that resulted in enhanced sensitivity to (control) DC-mediated killing. Specifically, we found that pretreatment of A20 lymphoma cells with a nitric oxide (NO) donor compound, PAPA-NO, markedly increased the sensitivity of tumor cells to consequent apoptosis mediated by DCs. This appeared to provide DCs with a preferred source of tumor antigens, with which, they were capable of activating specific T cells via a cross-presentation pathway. We have also discovered that multiple TNF family ligands participated in DC-mediated tumoricidal function and that tumor cell-expressed survivin may represent a critical downstream factor regulating the apoptotic sensitivity of tumor cells to DC-mediated apoptosis. When taken together, these studies provide novel details regarding mechanisms involved in DC anti-tumor effector function, and suggest two DC-based, combinational cancer therapies that target the effective cross-priming of therapeutic T cells. The results presented in this dissertation support an efficient model in which DCs may not only serve as the gatherers and presenters of antigens, but also the hunters as well, with tumoricidal activity mediated via TNF family ligands.

[Enhancement of Antigen Presenting Function of Dendritic Cells by IL-2 Gene Modification and Its Mechanism].

ANTITUMOR EFFECTS OF HUMAN IL-15 GENE MODIFIED LUNG CANCER CELL LINE

Enhancing Expression of Apex Gene by Il-2 in Mouse T Cells

Il-12 Augments Antigen-Dependent Proliferation Of Activated Lymphocytes-T

More efficient induction of antitumor T cell immunity by exosomes from CD40L gene-modified lung tumor cells.

Specific Activity of Cytotoxic T Lymphocyte in Mice Induced by Dendritic Cells after Mil-12 Gene Modification and Murine Colon Carcinoma RNA Transfection

Mechanism of Enhancement of the CTL Activity in Mice Co-Expressing CD80, CD86 and CD137Lgenes

Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8 + CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells

Lymphotactin Gene-Modified Bone Marrow Dendritic Cells Act As More Potent Adjuvants for Peptide Delivery to Induce Specific Antitumor Immunity

Immune Tolerance of Allogeneic T Cells Induced by Dendritic Cells Genetically Engineered to Express Iκ Bα Mutant

Specific Antitumor-Immunity Induced by Mil-12 Gene Modified Dendritic Cells Transfected with Murine Colon Carcinoma RNA

MODULATION OF TUMORICIDAL ACTIVITIES OF DENDRITIC CELLS TO ENHANCE ANTIGEN UPTAKE AND CROSS-PRESENTATION

Dendritic cell transfected with secondary lymphoid-tissue chemokine and/or interleukin-2 gene-enhanced cytotoxicity of T-lymphocyte in human bladder tumor cell S in vitro

Involvement of MHC class I molecule and ICAM-1 in the enhancement of adhesion and cytotoxic susceptibility to immune effector cells of tumor cells transfected with the interleukin (IL)-2, IL-4 or IL-6 gene

Enhancement of non-MHC restricted anti-tumor effect of immunocytes by dendritic cells

Coadministration of Interleukin 2 Plasmid Dna with Combined Dna Vaccines Significantly Enhances the Protective Efficacy Against Mycobacterium Tuberculosis

Enhanced Human T Lymphocyte Antigen Priming by Cytokine-Matured Dendritic Cells Overexpressing Bcl-2 and IL-12.

Enhanced Therapeutic Efficacy Of Tumor Rna-Pulsed Dendritic Cells After Genetic Modification With Lymphotactin

Comparative study on effect of astragulus injection and interleukin-2 in enhancing anti-tumor metastasis action of dendrite cells]

A Study on Enhanced Anti-Tumor Immunity Induced by High Level Expression of GM-CSF in 3LL Tumor Site of the Mice

GENETICALLY MODIFIED DENDRITIC CELLS INDUCED SPECIFIC CYTOTOXITY AGAINST HUMAN HCC CELLS IN VITRO